The global cancer biopsy market size is expected to reach USD 51.61 billion by 2030, registering a CAGR of 8.11% from 2024 to 2030. The advancement in molecular medicine has facilitated the creation of novel devices for the molecular characterization of cancers. As a result, the rising acceptance and approvals of liquid biopsies are anticipated to be significant driving forces behind the overall market growth.
Numerous emerging manufacturers are dedicated to developing instruments that can improve endoscopy-based cancer biopsies. For instance, in March 2023, BiBBInstruments AB, a Swedish company, established a strong presence in the cancer biopsy instruments market under the brand - EndoDrill. The company changed biopsy instruments that allow rapid and precise diagnosis of cancer patients related to existing biopsy instruments. Moreover, it offers biopsy instruments catering to core needles and flexible endoscopic biopsies. Such companies developing in the market are expected to upsurge the accessibility of cancer biopsy instruments.
The field of oncology-based genomic data analysis and personalized medicine is anticipated to witness lucrative prospects with the emergence of liquid biopsies. Regulatory bodies are actively backing the commercialization of these products and promoting their utilization in clinical settings due to the significant potential they offer. Liquid biopsy facilitates cancer detection through various body fluids, and the advancements in this technique have made it an appealing noninvasive approach for obtaining cancer biomaterials for diagnostic purposes.
The liquid biopsies segment is projected to experience rapid expansion in the upcoming years, driven by significant investments and strategic efforts from companies engaged in biopharmaceutical manufacturing and genomic data analysis. Emerging companies are showing a strong inclination towards forming partnerships with established industry participants like QIAGEN Bioinformatics, Fabric Genomics, Agilent Technologies, and SOPHiA Genetics. This collaborative trend is expected to further boost the overall market growth.
This product will be delivered within 1-3 business days.
Numerous emerging manufacturers are dedicated to developing instruments that can improve endoscopy-based cancer biopsies. For instance, in March 2023, BiBBInstruments AB, a Swedish company, established a strong presence in the cancer biopsy instruments market under the brand - EndoDrill. The company changed biopsy instruments that allow rapid and precise diagnosis of cancer patients related to existing biopsy instruments. Moreover, it offers biopsy instruments catering to core needles and flexible endoscopic biopsies. Such companies developing in the market are expected to upsurge the accessibility of cancer biopsy instruments.
The field of oncology-based genomic data analysis and personalized medicine is anticipated to witness lucrative prospects with the emergence of liquid biopsies. Regulatory bodies are actively backing the commercialization of these products and promoting their utilization in clinical settings due to the significant potential they offer. Liquid biopsy facilitates cancer detection through various body fluids, and the advancements in this technique have made it an appealing noninvasive approach for obtaining cancer biomaterials for diagnostic purposes.
The liquid biopsies segment is projected to experience rapid expansion in the upcoming years, driven by significant investments and strategic efforts from companies engaged in biopharmaceutical manufacturing and genomic data analysis. Emerging companies are showing a strong inclination towards forming partnerships with established industry participants like QIAGEN Bioinformatics, Fabric Genomics, Agilent Technologies, and SOPHiA Genetics. This collaborative trend is expected to further boost the overall market growth.
Cancer Biopsy Market Report Highlights
- In 2023, kits and consumables held the largest market share by product, and this dominance is projected to persist throughout the forecast period. The increased adoption of kits and consumables can be attributed to the notable shift from tumor biopsies to liquid biopsies.
- Tissue biopsies remain a fundamental aspect of the biopsy process and are widely utilized across various diagnostic applications. Furthermore, tumor biopsies are primarily employed for individual-level diagnosis and monitoring the efficacy of ongoing oncology treatments.
- In terms of application, breast cancer dominated the global market in 2023 and is expected to maintain its lead throughout the forecast period. Open surgical biopsy remains a reference standard for evaluating patients with suspicious breast lesions, owing to its established accuracy in diagnosing such conditions. Consequently, this segment's revenue is bolstered by its proven efficacy in breast lesion diagnosis.
- North America held the largest revenue share in 2023 owing to the concentrated pool of active organizations and cancer foundations. The strong network of government organizations and private cancer foundations in the U.S. has made significant contributions to the regional revenue generation capacity.
The leading players in the Cancer Biopsy market include:
- QIAGEN
- Illumina, Inc.
- ANGLE plc
- BD (Becton, Dickinson and Company)
- Myriad Genetics, Inc.
- Hologic, Inc.
- Biocept, Inc.
- Thermo Fisher Scientific, Inc.
- Danaher
- F. Hoffmann-La Roche Ltd.
- Lucence Health Inc.
- GRAIL, Inc.
- Guardant Health Inc.
- Exact Sciences Corporation
- Freenome Holdings, Inc.
- Biodesix (Integrated Diagnostics)
- Oncimmune
- Epigenomics AG
- HelioHealth (Laboratory for Advanced Medicine)
- Genesystems, Inc. (Genesys Biolabs)
- Chronix Biomedical, Inc.
- Personal Genome Diagnostics Inc.
- Natera, Inc.
- Personalis Inc.
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Cancer Biopsy Market Variables, Trends & Scope
Chapter 4. Cancer Biopsy Market: Product Estimates & Trend Analysis
Chapter 5. Cancer Biopsy Market: Type Estimates & Trend Analysis
Chapter 6. Cancer Biopsy Market: Application Estimates & Trend Analysis
Chapter 7. Cancer Biopsy Market: Regional Estimates & Trend Analysis by Type, Tube Material, Application, and End-use
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The leading players in the Cancer Biopsy market include:- QIAGEN
- Illumina, Inc.
- ANGLE plc
- BD (Becton, Dickinson and Company)
- Myriad Genetics, Inc.
- Hologic, Inc.
- Biocept, Inc.
- Thermo Fisher Scientific, Inc.
- Danaher
- F. Hoffmann-La Roche Ltd.
- Lucence Health Inc.
- GRAIL, Inc.
- Guardant Health Inc.
- Exact Sciences Corporation
- Freenome Holdings, Inc.
- Biodesix (Integrated Diagnostics)
- Oncimmune
- Epigenomics AG
- HelioHealth (Laboratory for Advanced Medicine)
- Genesystems, Inc. (Genesys Biolabs)
- Chronix Biomedical, Inc.
- Personal Genome Diagnostics Inc.
- Natera, Inc.
- Personalis Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | September 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 30.05 Billion |
| Forecasted Market Value ( USD | $ 51.61 Billion |
| Compound Annual Growth Rate | 8.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 25 |
